Bladder Disease Clinical Trial
Official title:
The Effect of Different Injection Site Maps on Intravesical Botulinum Toxin of Bladder
Verified date | February 2024 |
Source | Basaksehir Cam & Sakura Sehir Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Botulinum toxin injection into the bladder is used in current practice in urological diseases such as overactive bladder or interstitial cystitis. As far as is known, botulinum toxin injection sites have not been clearly defined. In this study, investigators are planning to compare botulinum toxin effectiveness with different injection site maps.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | October 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Older than 18 years - Interstitial cystitis patients - Overactive bladder Exclusion Criteria: - younger than 18 years |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Basaksehir Cam & Sakura Sehir Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overactive bladder-V8 questionnaire will be used for efficacy of treatment. | The questionnaire contains 8 questions and every question may be scored between 0 and 5. Additionally, male gender get 2 points more. Therefore, a patient may be get between 0 and 42 points. More score means worse complaint. | Estimated 1 month for every patient after treatment. | |
Primary | Urodynamics test will be assessed for efficacy of treatment. | Possible bladder contractions and residual volume will be measured in urodynamic testing to demonstrate effectiveness after treatment. The lack of pathological bladder contractions and normal residual urine mean better for patient and, show improving. | Estimated 1 month for every patient after treatment. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00210249 -
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
|
||
Recruiting |
NCT06167356 -
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
|
||
Recruiting |
NCT04153227 -
Osteoporosis, Trabecular Bone Score and Fracture Risk Assessment in Male Patients After Radical Cystectomy
|
||
Completed |
NCT04192474 -
Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy
|
N/A | |
Recruiting |
NCT06337942 -
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
|
N/A | |
Recruiting |
NCT03486639 -
Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity
|
||
Active, not recruiting |
NCT04167631 -
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
|
N/A | |
Completed |
NCT00615043 -
Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure
|
N/A | |
Completed |
NCT04200963 -
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
|
Phase 1 | |
Completed |
NCT03591367 -
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
|
N/A | |
Terminated |
NCT03065348 -
Perioperative Multimodal Care for Cystectomy Frail Patient
|
N/A | |
Recruiting |
NCT05726786 -
The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
|
Phase 3 | |
Completed |
NCT03257293 -
A Trial of a Modified Cystoscopy Method to Reduce Pain Perception
|
N/A | |
Recruiting |
NCT06395701 -
Trimodality Treatment in Bladder Cancer
|